Close Menu

NEW YORK (GenomeWeb) – China's BGI said this week that it has received a CLIA certificate of registration for its Hong Kong laboratory.

BGI said the certification will help it to expand its offering of clinical sequencing services for specific diseases, including cancer and Mendelian disorders. It will also be useful for genomics-based clinical trial testing as part of BGI's CRO pharma solutions, which support drug discovery and development for biopharmaceutical clients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.